Transparency Is Not Enough: How Can We Improve the Management of Financial Conflicts of Interest Between Pharma and Healthcare Sectors?

Clin Pharmacol Ther. 2021 Aug;110(2):289-291. doi: 10.1002/cpt.2126. Epub 2020 Dec 30.

Authors

Akihiko Ozaki^{1

2}, Anju Murayama¹, Hiroaki Saito³, Toyoaki Sawano⁴, Kayo Harada¹, Yuki Senoo¹, Kana Yamamoto¹, Tetsuya Tanimoto^{1

5}

Affiliations

¹ Medical Governance Research Institute, Minato-ku, Tokyo, Japan.
² Department of Breast Surgery, Jyoban Hospital of Tokiwa Foundation, Iwaki, Fukushima, Japan.
³ Department of Gastroenterology, Sendai Kousei Hospital, Sendai, Miyagi, Japan.
⁴ Department of Surgery, Jyoban Hospital of Tokiwa Foundation, Iwaki, Fukushima, Japan.
⁵ Department of Internal Medicine, Navitas Clinic Kawasaki, Kawasaki, Kanagawa, Japan.

PMID: 33377498
DOI: 10.1002/cpt.2126

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Conflict of Interest*
Disclosure / standards
Drug Industry / organization & administration*
Drug Industry / standards
Guidelines as Topic
Health Care Sector / organization & administration*
Health Care Sector / standards
Humans